AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy

Funding:
AvenCell Therapeutics has secured $112 million in Series B funding to advance its 'switchable' CAR-T cell therapy into clinical trials.

Innovation:
The 'switchable' CAR-T technology allows for more control over the therapy, potentially improving safety and efficacy by enabling the activation or deactivation of the CAR-T cells as needed.

Clinical Trials:
The funding will be used to conduct clinical trials to prove the effectiveness of this innovative approach.

Biotech Landscape:
This development highlights the ongoing innovation in the CAR-T cell therapy space, which includes the evaluation of kill switches to eliminate modified cells after their therapeutic use.

Industry Impact:
The success of AvenCell's 'switchable' CAR-Ts could significantly impact the biotech industry by offering a more controllable and potentially safer form of cell therapy.